Personalized neoantigen tumor vaccine(Ruijin Hospital)(Personalized neoantigen tumor vaccine(Ruijin Hospital)) - 在研适应症：晚期恶性实体瘤，胰腺癌_专利_临床

概要

基本信息

药物类型

个性化抗原疫苗、治疗性疫苗、mRNA疫苗

别名

mRNA-0217/S001

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病

在研适应症

晚期恶性实体瘤胰腺癌

非在研适应症-

原研机构

上海交通大学医学院附属瑞金医院

在研机构

上海交通大学医学院附属瑞金医院

非在研机构-

最高研发阶段早期临床1期

首次获批日期-

最高研发阶段(中国)早期临床1期

特殊审评-

登录后查看时间轴

关联

3

项与 Personalized neoantigen tumor vaccine(Ruijin Hospital) 相关的临床试验

NCT06496373

/ Recruiting早期临床1期IIT

Clinical Study of XP-004 Personlaized mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer

This study primarily aims to assess the safety and tolerability of XP-004 personalized mRNA vaccines encoding tumor neoantigens combined with PD-1 inhibitor as adjuvant therapy for chemotherapy-intolerant patients following radical pancreatic cancer resection.
Secondary objectives focus on evaluating preliminary efficacy through three parameters: 1) XP-004-induced antigen-specific CD4+/CD8+ T cell activation levels, 2) recurrence-free survival (RFS), and 3) overall survival (OS) in post-operative pancreatic cancer patients receiving this combination therapy.

开始日期2024-10-16

申办/合作机构

上海交通大学医学院附属瑞金医院

[+1]

NCT05916248

/ Recruiting早期临床1期IIT

Clinical Study of Personalized Tumor Vaccines mRNA-0217/S001 and Pembrolizumab in Patients With Advanced Solid Tumors

The main objective of this study was to observe and evaluate the safety and tolerability of mRNA-0217/S001 vaccine encoding personalized tumor neoantigens alone/in combination with Pembrolizumab injection for the treatment of advanced solid tumors. The secondary objective was to observe the preliminary efficacy of mRNA-0217/S001 personalized tumor vaccine in the treatment of advanced solid tumors with neoantigen-specific CD4+ and CD8+ T lymphocyte responses, objective tumor response rate (ORR) and disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) caused by mRNA-0217/S001 personalized tumor vaccine.

开始日期2023-12-20

申办/合作机构

上海交通大学医学院附属瑞金医院

[+1]

NCT05916261

/ Recruiting早期临床1期IIT

Clinical Study of Personalized Tumor Vaccines mRNA-0217/S001 and Pabolizumab in Patients With Advanced Pancreatic Cancer

The main objective of this study was to observe and evaluate the safety and tolerability of mRNA-0217/S001 vaccine encoding personalized tumor neoantigens alone/in combination with Pembrolizumab injection for the treatment of Advanced Pancreatic Cancer. The secondary objective was to observe the preliminary efficacy of mRNA-0217/S001 personalized tumor vaccine in the treatment of advanced solid tumors with neoantigen-specific CD4+ and CD8+ T lymphocyte responses, objective tumor response rate (ORR) and disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) caused by mRNA-0217/S001 personalized tumor vaccine.

开始日期2023-04-26

申办/合作机构

上海交通大学医学院附属瑞金医院

100 项与 Personalized neoantigen tumor vaccine(Ruijin Hospital) 相关的临床结果

登录后查看更多信息

100 项与 Personalized neoantigen tumor vaccine(Ruijin Hospital) 相关的转化医学

登录后查看更多信息

100 项与 Personalized neoantigen tumor vaccine(Ruijin Hospital) 相关的专利（医药）

登录后查看更多信息

100 项与 Personalized neoantigen tumor vaccine(Ruijin Hospital) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期恶性实体瘤	临床1期	中国	上海交通大学医学院附属瑞金医院	2023-12-20
胰腺癌	临床1期	中国	上海交通大学医学院附属瑞金医院	2023-04-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2021	N/A	星形细胞瘤	1	Personalized DNA neoantigen vaccine	醖鑰觸夢窪製窪衊夢齋(餘憲窪淵鬱蓋繭構醖遞) = grade 1 鏇鹽築簾簾願齋鑰範範 (願餘鏇鹽願餘衊網廠鏇 )	-	2021-05-28